WCN26-8685 Serum levels of CMPF, a protein-bound uremic toxin, across different kidney replacement modalities

Read full text Summarise with VIRAT
Authors: Beatriz Akemi Kondo Van Spitzenbergen, Rayane De Cássia Cagni Vicentin, Nadja Grobe, Andréa Novais Moreno-Amaral, Peter Kotanko
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The protein-bound solute 2-(2-carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic acid (CMPF), a metabolite derived from furan fatty acids, has been classified as a uremic toxin. Elevated CMPF levels have been reported in patients with chronic kidney disease (CKD), and emerging evidence suggests its potential impact on erythrocyte biology (Van Spitzenbergen, Nephrol Dial Transplant. 2025 Jun 30;40(7):1342-1349. https://doi.org/10.1093/ndt/gfae275). This study aimed to quantify total serum CMPF levels in individuals with CKD undergoing different renal replacement therapy modalities.

Fields of Study & Subjects

Dialysis and Renal Disease Management Acute Kidney Injury Research Parathyroid Disorders and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104542–104542
Publication date
25 March 2026
Language
EN